Browse Articles
Discover research articles across all indexed journals
Avelumab maintenance therapy in patients (pts) with advanced urothelial carcinoma (UC) in Japan: Subgroup analyses by prior chemotherapy regimen from post-marketing surveillance (PMS).
692 Background: Avelumab was approved as maintenance therapy for pts with advanced UC that has not progressed after prior first-line platinum-based chemotherapy based on results from the JAVELIN Bladder 100 phase 3 trial, which showed a significant overall survival (OS) benefit. PMS data showed the safety and effectiveness of avelumab maintenance therapy in clinical practice in Japan. We report post hoc analyses of PMS data in subgroups defined by prior chemotherapy regimen. Methods: This prospective, multicenter, observational PMS evaluated pts with advanced UC who received ≥1 dose of avelumab between Feb and Dec 2021. The observation period was ≤52 weeks from start of avelumab in all pts. Data were analyzed in subgroups defined by prior chemotherapy for advanced UC: gemcitabine + cisplatin (GC), gemcitabine + carboplatin (GCa), or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC). Pt characteristics were analyzed using descriptive statistics, and time-to-event analyses (from the start of avelumab maintenance therapy) used the Kaplan-Meier method. Results: The study cohort included 453 pts. Median age was 73 years (range, 21-91). Primary tumor site was bladder in 244 pts (53.9%) and upper tract in 209 (46.1%). Prior chemotherapy regimen was GC in 267 (58.9%), GCa in 163 (36.0%), and ddMVAC in 9 (2.0%). In chemotherapy subgroups, age was ≥75 years in 86 (32.2%), 89 (54.6%), and 1 (11.1%), and renal impairment was reported in 77 (28.8%), 82 (50.3%), and 2 (22%), respectively. At data cutoff (Mar 6, 2024), median duration of avelumab maintenance therapy was 5.1 mo (IQR, 2.3-12.0), 128 pts (28.3%) remained on avelumab, and 184 (40.6%) had received subsequent treatment. Prespecified adverse drug reactions (ADRs) of any grade were observed in 144 (31.8%) overall, and in 93 (34.8%) in the GC subgroup, 45 (27.6%) in the GCa subgroup, and 3 (33.3%) in the ddMVAC subgroup; ADRs were grade ≥3 in 36 (7.9%) overall, and in 22 (8.2%), 12 (7.4%), and 0 in subgroups, respectively. Median time to treatment failure was 4.6 mo (95% CI, 3.8-5.3) overall, and 4.6 mo (95% CI, 3.4-5.6), 4.6 mo (95% CI, 3.1-6.5), and 5.1 mo (95% CI, 1.4-11.8), in subgroups. Median OS was not reached in any subgroup; the 1-year OS rate was 77.9% (95% CI, 73.7-81.5) overall, and 79.6% (95% CI, 74.3-84.0), 73.8% (95% CI, 66.2-80.0), and 88.9% (95% CI, 43.3-98.4) in subgroups. Conclusions: This PMS represents the largest prospective observational study of avelumab maintenance therapy in pts with advanced UC in Asia. Post hoc analyses showed the acceptable safety and effectiveness of avelumab maintenance therapy in subgroups defined by prior chemotherapy regimen. Findings are consistent with analyses from JAVELIN Bladder 100 and support the favorable benefit-risk profile of avelumab in clinical practice in Japan, irrespective of prior chemotherapy regimen.
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
PURPOSE Human epidermal growth factor receptor 2 (HER2)–targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 expression. No definitive treatment guidance currently exists beyond second line. Trastuzumab duocarmazine (T-Duo) is a third-generation, HER2-targeted antibody-drug conjugate that demonstrated efficacy and acceptable safety in phase I studies of heavily pretreated patients with HER2+/HER2-low breast cancer. METHODS In this open-label, randomized, phase III trial, T-Duo was compared with physician's choice (PC) in patients with unresectable locally advanced/metastatic HER2+ breast cancer with progression during/after ≥2 HER2-targeted therapies or after trastuzumab emtansine (T-DM1). The primary endpoint was progression-free survival (PFS) by blinded independent central review. RESULTS In total, 437 patients were randomly assigned 2:1 to T-Duo (n = 291) or PC (n = 146). The median age was 56.0 years (range, 24-86); most patients (93.6%) had metastatic disease. The median time from diagnosis of metastatic disease to trial entry was 3.5 years; the median number of prior HER2-targeted therapies in metastatic setting was three. The median PFS was 7.0 months (95% CI, 5.4 to 7.2) with T-Duo versus 4.9 months (95% CI, 4.0 to 5.5; hazard ratio [HR], 0.64 [95% CI, 0.49 to 0.84]; P = .002) with PC. PFS benefit was maintained across most predefined subgroups. The median overall survival (first analysis) was 20.4 (T-Duo) versus 16.3 months (PC; HR, 0.83 [95% CI, 0.62 to 1.09]; P = .153). Objective response rate was 27.8% (T-Duo) versus 29.5% (PC); other efficacy end points—clinical benefit rate, duration of response, and reduction in target lesion measurement—tended to favor T-Duo. Grade ≥3 treatment-emergent adverse events occurred in 52.8% (T-Duo) versus 48.2% (PC). CONCLUSION Treatment with T-Duo was manageable, but tolerability was affected by prevalent ocular toxicity, leading to a higher discontinuation rate in the T-Duo arm. T-Duo significantly reduced the risk of progression in patients with advanced HER2+ breast cancer who have progressed during/after ≥2 HER2-targeted therapies or after T-DM1.
Management of relapsed stage I seminomatous germ cell tumor with retroperitoneal or pelvic only relapse.
630 Background: For patients (pts) with stage 1 seminomatous germ cell tumor (SGCT) on active surveillance (AS), front-line therapy depends on the location and extent of relapse. We describe the characteristics and management of pts on AS with stage I SGCT with relapse in the retroperitoneum (RP) or pelvis only. Methods: The prospectively maintained Indiana University testicular cancer database was queried for pts with stage 1 SGCT on AS w/ RP or pelvic only relapse between 1990-2024. Pts were categorized into a chemotherapy, surgery, or radiation (XRT) group based on treatment at relapse. Comparisons between groups were done using Chi-square tests for categorical variables or Kuskal-Wallis test for continuous variables. Kaplan-Meier method was used to analyze progression-free survival (PFS) and overall survival (OS) using the log rank test to compare groups. Results: We identified 71 pts with stage 1 SGCT on AS w/ relapse in the RP or pelvis only. The median age at diagnosis was 37.2 yrs (range, 19.5-74.5). IGCCCG risk was good in all pts. At time of relapse, 37 pts (52.1%) were treated with chemo, 20 with surgery (28.2%), and 14 (19.7%) with XRT. The median time to relapse on stage I AS for pts treated with chemo was 9.5 months (0.84-91.7) compared to 19.9 months (1.6-60.2) with surgery and 13.1 months (4.6-48.8) with XRT (p=0.13). Chemo regimens used were BEP X 3 (62.2%), EP X 4 (21.6%), BEP X 4 (2.7%) and other (13.5%). 68 pts (95.8%) relapsed in the RP; 3 (4.2%) relapsed in the pelvis only. All 9 pts with lymph node (LN) size >5 cm were treated with chemo. In the 32 pts with LN size <3 cm, 12 (37.5%) were treated with surgery, 12 (37.5%) with chemo, and 8 (25%) with XRT. 11 total pts (15.5%) relapsed after front-line therapy and thus required multimodality treatment. This included 8 (21.6%) in the chemo group who relapsed; 2 out of 8 required RPLND while 6 were treated with salvage or high dose chemotherapy. 1 patient (5%) in the surgery group relapsed and required chemotherapy. In the XRT group, 2 pts (14.3%) relapsed; 1 was treated with salvage chemo and 1 with surgery. With a median follow-up time of 3.03 yrs (0-14.8), the 2-yr PFS for pts treated with chemo was 73.8%, surgery was 95%, and XRT was 92.3% (p=0.14). 2-yr OS was 100% for all treatment groups (p=0.58). Conclusions: In pts on AS with stage I SGCT w/ RP or pelvic only relapse, there was no difference in survival outcomes based on front-line therapy received. In this cohort of pts carefully selected for RPLND, the majority were cured with single-modality therapy; most of these pts had RP lymph nodes <3cm with a longer median time to relapse while on AS.
Pathological complete response and potential for bladder preservation by theranostic instillation therapy targeting CXCR4 in combination with systemic chemotherapy: The Bladder BRIDGister experience.
691 Background: Patients with muscle invasive urothelial carcinoma (MIBC) achieving pathological complete response (pCR) upon neoadjuvant chemotherapy (NACT) have improved prognosis. Previously we did show that luminal tumors respond better to NACT (Ecke et al 2022), while chemoresistant tumors express radioligand targets CXCR4 and FAP. First-in-Human treatment of chemotherapy resistant T4 MIBC using two cycles of Lu 177 FAP combined with one cycle of pembrolizumab results in durable complete response (Baum et al, submitted). The objective of this study was to eradicate treatment naïve T2a MIBC with limited probability to respond to chemotherapy by adding intravesical Lu 177 CXCR4 instillation into the bladder before first NACT cycle to justify subsequent adopted clinical trials. Methods: A reference cohort (n=100) for subtype classification was constructed. RNA from FFPE tissues was extracted, relative gene expression of luminal and non-luminal target were analyzed by RT-qPCR. FFPE tissue from initial TURB of MIBC patients under evaluation for subsequent therapy were analyzed accordingly and individual target mRNA were added to the cluster analysis to determine subtype and target expression level. PET/CT Imaging by Ga 68 CXCR4 was performed in selected patients. In case of tumor specific, high uptake subsequent Lu 177 CXCR4 was instilled one week before initiation of ddMVAC. Response was evaluated by Ga 68 CXCR4 PET/CT and control resections by TURB. Results: A luminal pT2 G3 MIBC patient with elevated CXCR4 expression level by RT-qPCR and validated by immunohistochemistry, who was predicted to be unresponsive to NACT, was selected for CXCR4 instillation therapy. Subsequent Ga 68 CXCR4 whole body PET/CT proved tumor specific uptake and excluded nodal involvement as well as distant metastasis. Thereafter 4GB Lu 177 CXCR4 was applied via catheter as intravesical Radio-Ligand-Therapy (iRLT) followed by three cycles ddMVAC. Thereafter a control Ga 68 CXCR4 was performed before starting the planned second cycle of iRLT and ddMVAC. Intravesical Ga 68 CXCR4 PET/CT revealed complete response, with no tumor uptake being visible anymore. TURB including muscle tissue revealed complete absence of malignancy with only inflammatory immune reaction being left after RLT based NACT. Conclusions: Combination of molecular in vitro diagnostics identifies high risk MIBC with elevated CXCR4 target gene expression, that exhibit high radioligand uptake in vivo and are amenable for intensified treatment by adding iRLT to systemic ddMVAC treatment. First clinical results are promising and justify clinical approaches as part of phase 1 / 2 clinical trials within the Bladder BRIDGister study group with the ultimate goal of bladder preservation after pCR to neoadjuvant combination therapies.
Real world toxicity profile of enfortumab vedotin (EV) with or without pembrolizumab (P) in ultra elderly urothelial carcinoma (UC) patients (pts).
734 Background: EV is an antibody drug conjugate that was approved in the United States as monotherapy for pretreated advanced UC and, then, in combination with P in untreated pts. However, EV is associated with multiple toxicities, which are mostly non-overlapping with those of P. In the EV-302 study, grade (G) 3 or higher treatment-related adverse events (TRAEs) occurred in 55.9% of pts and led to treatment discontinuation in 35.0% of those on EV+P. Pts aged 80 years or older (i.e. the ultra elderly) are a special population, who may be particularly vulnerable to EV toxicity. Methods: This is a retrospective analysis of UC pts, who received EV monotherapy or EV+P at 2 academic institutions in Southern California from 12/2019 to 9/2024. Pts had to be aged 80 years or older at EV start to qualify and must have received at least 1 EV dose. Toxicity was graded using the CTCAE version 5 criteria. Results: A total of 26 pts were included, with 83.6% being male. Median age was 86.5 years [range, 80 to 97], with 38.5% of pts aged 80-84 years (group 1), 46.2% aged 85-89 years (group 2), and 15.4% aged over 90 years (group 3). 53.8% identified as Caucasian, 23.1% as Asian, 15.4% as Hispanic, and 7.7% as “other”. 69.2% received EV monotherapy and 30.8% EV+P. In those on EV alone, 88.9% had a prior PD-1/PD-L1 inhibitor. At time of data cut off, 27.0% of pts were still receiving EV. Median number of EV infusions given was 10.5 [range, 2 to 25], while median number of weeks on EV was 19.5 [range, 1 to 52]. In group 1, starting EV dose was 1.25 mg/kg in 30.0% of pts and 1.0 mg/kg in 70.0%. In group 2, starting EV dose was 1.25 mg/kg in 16.7% of pts, 1.0 mg/kg in 25.0%, 0.75 mg/kg in 41.7%, and 0.5 mg/kg in 16.7%. In group 3, starting EV dose was 1.25 mg/kg in 25.0% of pts, 1.0 mg/kg in 50.0%, and 0.5 mg/kg in 25.0%. After EV start, 50.0% had at least 1 EV dose reduction, 42.3% had at least 1 dose delay, and 30.8% had EV discontinued due to TRAEs. Toxicity severity in the overall study population was as follows: G0 in 26.9%, G1 in 30.8%, G2 in 26.9%, and G3 in 15.4%. No G4/5 toxicities were noted. Starting EV dose and associated toxicity are outlined in the table. Specific TRAEs included neuropathy in 34.6% of pts, ocular symptoms in 19.2%, rash/pruritus/fatigue/abnormal electrolytes in 15.4% each, nausea and diarrhea in 3.8% each. Conclusions: Despite its small sample size and retrospective nature, this dataset did not identify any excessive or unexpected toxicity in the ultra elderly population. More pts in groups 2/3 received up-front EV dose reduction, with less G2/3 TRAEs noted at lower starting EV doses. Up-front dose reduction of EV may be a good strategy to mitigate TRAE risk. Starting EV dose and associated EV-related TRAEs. Dose (mg/kg) % of pts % of pts with G0 TRAEs % of pts with G1 TRAEs % of pts with G2 TRAEs % of pts with G3 TRAEs 1.25 23.1 16.7 0 66.7 16.7 1.0 46.2 25.0 33.3 25.0 16.7 0.75 19.2 40.0 40.0 0 20.0 0.5 11.5 33.3 66.7 0 0
Early detection of recurrent prostate cancer using 18F-DCFPyL PET/CT PET/CT in patients with minimal PSA levels.
344 Background: PSMA PET imaging is a highly sensitive and specific imaging tool for detecting prostate cancer, especially in biochemical recurrence (BCR). This has led to growing interest in utilizing PSMA PET for patients with minimally detectable PSA levels following definitive treatment as conventional imaging rarely localizes recurrent disease in this range, potentially delaying diagnosis and appropriate management. However, there is limited literature on the detection rate of 18F-DCFPyL at very low PSA levels in the BCR setting. Methods: This is a pooled retrospective analysis of patients from investigator-initiated trials at West Los Angeles Veterans Affairs and the phase III CONDOR trial with minimal PSA levels. Patients included had 18F-DCFPyL PET/CT at minimal PSA values (0.05 to 0.5 ng/ml). BCR was defined as rising PSA and patients were included irrespective of prior conventional imaging findings. The PET/CT scan reads were assisted by the automated Prostate Cancer Molecular Imaging Standardized Evaluation (aPROMISE) platform. The results were verified by an experienced and independent nuclear medicine physician. Primary analysis focused on the detection rate defined as the number of patients with positive PSMA lesions relative to total number of patients with BCR. Results: In total 129 patients were identified, 36 with PSA levels ranging from 0.05 to 0.2 ng/ml, and 93 with PSA levels >0.2 to 0.5 ng/ml. The site of positive findings, the intensity and volume of uptake in the 18F-DCFPyL PET/CT scan are detailed in the table below. Conclusions: 18F-DCFPyL PET/CT demonstrates high detection rate for recurrent prostate cancer even in patients with minimally detectable PSA levels, highlighting its potential as a valuable tool in early identification of metastatic disease. These findings suggest that current thresholds for initiating PSMA PET/CT imaging in BCR patients may need reconsideration to optimize early detection and subsequent clinical management. Further studies are necessary to refine guidelines and assess the cost-effectiveness of incorporating PSMA imaging at very low PSA levels. 0 – 0.2 (N=36) 0.2 – 0.5 (N=93) Total Detection Rate 13 (36%) 47 (51%) Prostate Bed 3 (8%) 4 (4%) Lymph Node Only 5 (14%) 29 (31%) Lymph Node and Bone 12 (33%) 39 (42%) Bone Only 8 (22%) 14 (15%) Visceral (Lung or Liver) 1 (3%) 10 (11%) Total SUVmean 3.8 4.2 Total SUVmax 10.9 12.4 Total disease volume (mean) 4.9 ml 1.9 ml
Analysis of gene expression signatures in prostate cancer prior to liver metastases.
206 Background: It has been recognized that as a prostate cancer (PCa) metastasizes to bone, it begins to express bone-specific proteins such as osteopontin, bone sialoprotein, and osteocalcin. This process is known as osteomimicry. Liver metastases (LM) are associated with the poorest clinical outcomes and affect 25% of PCa patients at autopsy. We hypothesized that PCa that metastasize to the liver express liver-specific genes prior to liver metastasis – a process we have named “hepatomimicry”. Methods: We have curated a list of 23 putative genes that are both primarily expressed in the liver and found in RNA-seq data from over 3000 PCa samples. Initial sources included the PCa transcription atlas (n = 2115), West Coast/SU2C Dream Team (n = 210), neuroendocrine PCa from cBioPortal (n = 49), and TEMPUS RNA-seq data generated specifically for Cedars-Sinai (n = 88). In each dataset, for the 23 hepatomimicry genes, we used recursive feature elimination and a t-test to discriminate between PCa LM and non-liver visceral metastases. In datasets with count-level data, we performed differential gene expression analysis with DeSeq2 and gene set enrichment analysis (GSEA) on identified differentially expressed genes. Results: In three different datasets, MAT1A, ELF3, and WEE1 were found to be either optimal genes for discriminating between these two groups or significantly different by t-test and were more highly expressed in LM. 270 genes were downregulated and 437 genes were upregulated in liver metastases (FDR q-value < 0.05, log2 fold change > 1 for upregulated and < -1 for downregulated). Subsequent GSEA found that liver-specific gene sets are highly enriched in the genes upregulated in LM, and endothelial cell genes are strongly downregulated. Conclusions: The initial results indicate that a three-gene subpanel of our initial set have predictive power for LM against other visceral metastases in PCa.While hepatocyte infiltration may impact the characterization of these samples by yielding a strong signal for liver-specific gene expression signature, confirmation of this finding remains important. Ongoing work is directed at confirming this signature in single-cell RNA-seq from PCa LM. Our work may be adaptable to developing diagnostic technologies such as liquid biopsies that may enhance the identification of patients who may have occult LM or that may develop LM as part of their natural history so that interventions may be enacted in a more timely manner.
Patient characteristics and survival in primary prostate sarcomas: An analysis of the SEER database.
271 Background: Primary prostate sarcoma (PPS) is a rare neoplasm of prostate and is associated with poor survival outcome. Methods: We conducted an analysis of patients with PPS in the Surveillance, Epidemiology, End Results (SEER) database from year 2000 to 2020. Patients were identified by using the primary cancer site codes for prostate as well as histological codes (ICD-O-3) that matches the list of sarcoma histology found in the NCCN soft tissue sarcoma and bone cancer guidelines. Data for demographics, disease extent and median overall survival (OS) were obtained. Sarcomas mixed with carcinomas, so-called carcinosarcomas, were included in the analysis. OS data of prostate adenocarcinoma from same database were obtained for a comparison. Results: During the period analyzed, a total of 1,120,527 patients with primary prostate neoplasms were identified. Among them, 239 patients (0.0002%) had PPS. Majority were Caucasian (67.8%) followed by Hispanics (13.4%) and African Americans (8.8%). The most common histology was rhabdomyosarcoma (28.5%), followed by leiomyosarcoma (21.8%), carcinosarcoma (16.7%), and unspecified sarcomas (8.8%).Among 221 patients with known extent of disease, 29.4%, 37.1% and 33.5% had localized, locoregional and distant metastatic disease, respectively. Overall, PPS was associated with worse OS than prostate adenocarcinoma (28 months vs. 183 months, P<0.01). OS for patients with localized, regional, and distant diseases were 54, 39, and 18 months, respectively (P=0.04). Patients with carcinosarcomas had worse OS than those with pure sarcomas (15 months vs. 34 months, P<0.001). Among patients with locoregional disease, 19 (14.2%) received chemotherapy only, 84 (62.7%) received surgery only, and 31 (23.1%) received both chemotherapy and surgery. Median OS was not reached in those with locoregional disease who did not receive surgery while it was 44 months in those who received surgery (P=0.055). As for those with distant metastasis, 37 (56.1%) received chemotherapy only, 13 (19.7%) received surgery only, and 16 (24.2%) received both chemotherapy and surgery. Median OS for those with metastatic disease who received chemotherapy versus no chemotherapy was 9 months versus 19 months (P=0.063). Conclusions: PPS was rare and associated with worse survival outcome compared with prostate adenocarcinomas. Carcinosarcomas were less common than pure sarcomas and were associated with worse survival than pure sarcomas.
A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer, (HCRN GU18-343) ABATE study.
800 Background: Atezolizumab (A) has demonstrated single agent activity as neoadjuvant therapy (NAT) for muscle invasive urothelial carcinoma (MIUC) (ABACUS trial). Cabozantinib (C) has a unique immunomodulatory profile that may foster anti-tumor immunity and has demonstrated clinical activity as monotherapy and in combination with A. We hypothesized that the combination of C and A as NAT for MIUC would improve pathologic response rate (pRR) compared to single-agent A. Methods: This open-label, single arm, multi-center study investigated the efficacy and safety of C 40 mg PO daily with A 1200mg every 3 weeks for 9 weeks as NAT for cT2-T4aN0/xM0 MIUC. Eligibility required patients (pts) to be cisplatin-ineligible or decline cisplatin, with UC as the predominant histology (≥ 50%). Primary endpoint was pRR defined as no residual muscle-invasive cancer in the surgical specimen (< ypT2); patients with progression prior to cystectomy were counted as non-responders. pRR was to be compared to the 39% response rate with the single agent A using a Bayesian evaluation with a Beta (0.5, 0.5) prior. Secondary endpoints were safety and toxicity, pathologic complete response rate (pCR, ypT0N0M0) and event-free survival (EFS). Exploratory end points included patient-reported outcomes and outcome associations with biomarkers. Results: From Feb 2021 to July 2024, 46 pts enrolled at 5 sites. 2 pts were deemed ineligible, and 6 pts did not proceed with cystectomy for reasons other than progression (4 pts opted for bladder preservation, 1 pt died from causes unrelated to tx and 1 pt still undergoing tx). Median follow up is 14 mo. At study entry median age was 71 yrs, 21% were female, 98% Caucasian and 71% were cisplatin ineligible, with T2, T3 and T4 disease in 73%, 18% and 9% respectively. Histology included pure urothelial cancer (56%), squamous (18%), glandular (3%), micropapillary (18%) and plasmacytoid (5%) differentiation. Among 35 pts who underwent cystectomy, 32 (91%) / 3 (9%) completed 3 and 2 doses of A and 15 (43%) / 32 (91%) completed 9 and at least 6 weeks of C. Adverse events are being analyzed. The estimated pRR was 29.5% (95% CrI 16.5% - 44.5%) and the pCR was 20.8% (95% CrI 9.4% - 35.3%). The pCR was lower in pts with variant histology compared to pure UC (13 vs 25%; p=0.39). 2-year EFS was 68.4% (95% CI, 47.7-82.3%). Conclusions: C+A has modest activity as NAT in MIUC and did not meet the pre-specified primary endpoint for pRR. Biomarkers studies are planned. Clinical trial information: NCT04289779 .
OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC).
TPS305 Background: This is a Canadian, multi-center study that investigates whether addition of ADT to RDT improves oncological outcomes in early romCSPC. The primary outcome is a 36-month composite Progression-free survival (cPFS). Secondary outcomes include metastasis-free survival, time to salvage therapy, time to castrate-resistant PC, OS, Quality of Life and toxicity. Methods: Population: Patients with biochemical recurrence after definitive or adjuvant/salvage radiotherapy for localized prostate cancer (PC) with oligo-metastatic disease (≤5 sites) without or with local recurrence. All patients will be staged with conventional imaging (CT/BS), mpMRI, PSMA-PET and biopsy of the prostate if in situ. Randomization: Patients are randomized 1:1 to RDT versus RDT+ADT for 12 months and stratified for, i) presence of local recurrence (Y/N), ii) volume of metastatic disease [0 (local recurrence alone) versus 1-3 versus 4-5 metastases]. iii) treatment centre, and iv) metastasis detected on conventional imaging (Y/N). Interventions: RDT options include Stereotactic Body Radiotherapy (SBRT), hypo-fractionated radiotherapy (HFRT), brachytherapy and surgical resection. Concurrent and adjuvant ADT involves four 3-month leuprolide acetate injections. Statistics: A clinically meaningful improvement for the use of ADT is defined as an improvement in the 30-month cPFS of ≥20% (from 50% to 70%). With an expected accrual period of 3 years, an additional 1 year of follow-up, a 1-sided log-rank test with α=0.05 would have over 80% power to distinguish between the two group with 73 patients in each arm. This number is inflated by 10% for stratification factors and patients lost-to-follow-up, for a total of 162 patients. Coordination: The study is coordinated by the Ontario Clinical Oncology Group (OCOG) and is expected to open in 10-12 institutions across Canada. This trial will provide evidence on the impact of ADT in romCSPC managed with optimal recurrence directed therapy. Findings will support phase III trial design to help define the optimal management of romCSPC in the future. Clinical trial information: NCT06654336 .
A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib + pembrolizumab or avelumab in first line therapy (PREPARE; AIO-NZK-0115/ass).
523 Background: Tyrosine kinase (TKI) and immune checkpoint inhibitors (CPI) are first-line options in metastatic renal cell carcinoma (mRCC). Most patients (pts) experience adverse events (AE) and 20-30% discontinue therapies due to AEs. We tested whether proactive onco-coaching (POC) improved quality of life (QoL) in patients with medical treatment. Methods: Adult treatment-naïve mRCC pts who were candidates for sunitinib (SU), axitinib + avelumab (AA) or axitinib + pembrolizumab (AP) were eligible. Treatment and modifications were at the physician's discretion. Pts were 1:1 randomized to POC by a trained nurse (8 visits of structured interviews educating on preventive, preemptive and supportive measures, and phone call follow-up for a total of 24 wks) or standard of care (SOC). Primary endpoint was the fraction of pts with QoL improvement (QOLI) by ≥3 points (minimal important difference: MID) of the FKSI-15 score. Secondary endpoints consisted of patient reported outcomes (PRO: FACT-G, EQ-5D), time to QOLI, efficacy, survival and safety (CTCTAE 4.03). The planned sample size was 430 pts. Log rank analyses were employed for time to event endpoints and Fisher exact tests for categorical data. Results: Between 2016 and 2023, 113 pts were included. Median age was 72 and 68y (POC vs. SOC). 44% had a Charlson Comorbidity Index (CCI) ≥2. MSKCC good/intermediate/poor risk were 21/61/12%. 86% had clear cell histology. Of 110 treated patients, 39% and 61% received SU or AXI-CPI (AA or AP). FKSI-15-completion rate was 85%. 80 pts (73%) had ≥2 PRO assessments and were evaluable for the primary endpoint. There was no difference in QOLI between POC and SOC (43.6% vs. 41.5%; p=0.95). Mean baseline FKSI-15 score was similar between arms, as were ORR (38.2 [95% CI 25.4-52.3] vs. 34.5% [95% CI 22.2-48.6]; p=0.96) and PFS (11.1 [95% CI 8.3- 18.9] vs. 9.2 mo [95% CI 5.6-14.6]; p=0.21). Overall survival was favored by POC (median 49.6 [95% CI 30.6- 61.6] vs. 25.4 mo [95% CI 17.8-NC]; p=0.11). Stratification by CCI had no relevant effect on OS in the POC arm (p=0.26), while pts. with CCI ≥2 had poorest OS in the SOC arm (15.7 vs. 33.4 mo; p=0.002). Treatment related AEs of any or ≥3 grade affected 96.4% and 52.7% with POC and 85.5% and 36.4% with SOC. Discontinuation due to toxicity between POC vs. SOC occurred for TKI in 7.3 vs. 9.1% and for CPI in 18.2 vs. 5.5% pts. Conclusions: Target patient accrual was not reached, and POC did not improve the rate of QoL responders or treatment efficacy. However, there was a trend towards a considerable extension of OS in the POC group, suggesting an overall beneficial impact of proactive coaching compared to standard reactive therapy management. Comorbid patients putatively benefit most from pro-active coaching, which warrants further studies. Clinical trial information: NCT03013946 .
Population-adjusted network meta-analyses (NMA) to evaluate the efficacy of treatment alternatives for metastatic hormone-sensitive prostate cancer (mHSPC).
267 Background: Existing NMA in mHSPC compare treatments assuming homogeneity in treatment effect modifiers across study populations. However, evidence suggests that these effects vary in mHSPC. This study employs the recent methods of multilevel network meta-regression (ML-NMR) and network meta interpolation (NMI) to adjust for population differences and predict relative effect estimates for an ARASENS-like target population. Methods: We used a systematic literature review to identify studies for our NMA on overall survival (OS) in mHSPC. We applied ML-NMR to adjust for imbalances in treatment effect modifiers by integrating individual patient data (IPD) regression from the ARASENS trial across the covariate distributions of comparator studies. The IPD was reconstructed from Kaplan-Meier curves for aggregate data studies, incorporating covariates age, ECOG performance status, Gleason score, and disease volume. Utilizing the same set of variables, NMI was employed to analyze subgroup data from comparator studies using reported hazard ratios. Results: Twelve studies were identified for inclusion in our analyses. The ML-NMR demonstrated a significant benefit for the darolutamide (daro) triplet compared to enzalutamide + ADT, apalutamide + ADT, abiraterone + ADT, and the abiraterone triplet in the ARASENS-like population. However, in the NMI analysis, the daro triplet was significantly favored over abiraterone + ADT when compared to other commonly utilized alternatives (Table). A key strength of the ML-NMR over NMI is that it only requires baseline characteristics to be reported, rather than subgroups which were relatively poorly reported or not powered to detect statistically significant differences. The NMI method suffered due to incomplete subgroup data, with full data for effect modifiers available in 8/12 studies. Conclusions: Both ML-NMR and NMI analyses support triplet benefit with ADT + docetaxel + daro in improving OS for patients with mHSPC. The evidence from ML-NMR is particularly robust, benefiting from the better covariate data and the attendant decrease in uncertainty. Hazard ratio from ML-NMR and NMI. Daro + docetaxel + ADT versus ML-NMR: OSHR (95% CrI) NMI: OSHR (95% CrI) SNA+ADT 0.28 (0.17, 0.46)* 0.36 (0.23, 0.56)* ADT 0.43 (0.32, 0.60)* 0.51 (0.39, 0.65)* Docetaxel + ADT 0.57 (0.42, 0.77)* 0.68 (0.57, 0.80)* Enzalutamide + ADT 0.64 (0.44, 0.96)* 0.80 (0.57, 1.11) Apalutamide + ADT 0.68 (0.46, 1.00)** 0.75 (0.55, 1.03) Abiraterone + ADT 0.65 (0.45, 0.92)* 0.65 (0.52, 0.81)* Abiraterone acetate + docetaxel + ADT 0.66 (0.47, 0.93)* 0.89 (0.59, 1.34) CrI: credible interval, SNA: standard nonsteroidal antiandrogen, ADT: androgen deprivation therapy, *upper CrI did not cross the line of no effect, **rounding, upper CrI limit treated as below 1.00.
Phase I dose-escalation study of the next-generation nectin-4 targeting antibody–drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid tumors.
807 Background: Linker conjugation chemistry is a key determinant of antibody–drug conjugate (ADC) activity and tolerability. Linkers must be stable in the systemic circulation and allow efficient drug release at the target site for maximal intra-tumoral drug delivery. CRB-701, a next-generation nectin-4 targeted ADC, has third-generation linker technology that is specifically designed to reduce the dose-limiting toxicities (DLTs) reported with ADCs (e.g. enfortumab vedotin [EV]). In nonclinical studies, CRB-701 demonstrates preferential internalization-mediated payload release and a longer half-life than EV, which may reduce free monomethyl auristatin E (MMAE)-related toxicities and enable less frequent dosing. Following the first-in-human study (SYS6002-01), we present results of a phase I dose-escalation study conducted in a Western population. Methods: A Bayesian Optimal Interval design with 4 dose groups (1.8, 2.7, 3.6 and 4.5 mg/kg; each once every 3 weeks) was used to determine the maximum tolerated dose and the optimal doses for phase II evaluation (CRB-701-01; ClinicalTrials.gov identifier, NCT06265727). Patients with advanced solid tumors who failed or were intolerant to standard treatment were enrolled. Retrospective H-scores were obtained to confirm nectin-4 positivity. Safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity were assessed. Results: Patients with metastatic urothelial cancer, cervical cancer, endometrial cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer or triple-negative breast cancer were enrolled (N = 31). Patients had failed all potentially available, appropriate prior therapies. All 4 dose cohorts were enrolled; maximum patient follow-up was 23 weeks. No DLTs occurred. Most adverse events (AEs) were grade 1 or 2 in severity. Grade 1 or 2 treatment-related AEs reported in >20% of patients included corneal epithelial lesions, hematuria, hypertriglyceridemia, hyponatremia, proteinuria, anemia and dry eye. Skin rash (grade 1 or 2), neutropenia, fatigue and peripheral neuropathy were less frequent than expected for an MMAE-based ADC; longer-term data will be reported at the congress. CRB-701 demonstrated linear PK across all doses with limited accumulation. Antitumor responses were observed at multiple doses, with the first partial response at the lowest 1.8 mg/kg dose (confirmed responses will be presented). Conclusions: PK, safety andefficacy observations are consistent with those from a previous study in Han Chinese patients. CRB-701 was well tolerated and, relative to EV at similar doses, demonstrated signs of a differentiated PK profile, including a longer half-life and lower free MMAE levels. CRB-701 development will continue to dose expansion. Clinical trial information: NCT06265727 .
The prognostic utility of preoperative β2 microglobulin in patients with renal cell carcinoma.
565 Background: β2 microglobulin is a nonglycosylated protein synthesized by all nucleated cells. It has been utilized as a tumor marker in several different malignancies, however, studies examining its role in renal cell carcinoma (RCC) are limited. Methods: Using the Emory kidney cancer database, patients with any stage or histology RCC who underwent partial or radical nephrectomy from 2000 to 2022 and had an available β2 microglobulin within 90 days before surgery were included. β2 microglobulin ≥ 2.34 mg/L was considered elevated. Patient and surgical characteristics were recorded. Kaplan-Meier curves and multivariable Cox hazards models were used to assess the association between an elevated β2 microglobulin and overall (OS) and cancer-specific survival (CSS). Subgroup analysis was performed based on renal function (estimated glomerular filtration rate (eGFR) ≤ or > 60 mL/min/1.73m 2 ) and metastatic disease status. Results: Of 429 patients who met inclusion criteria, 178 (41.5%) had an elevated preoperative β2 microglobulin. After adjusting for confounders, an elevated β2 microglobulin was independently associated with worse CSS (HR 2.08 [95% CI 1.20–3.60]; p = 0.009) and OS (HR 1.58 [95% CI 1.03–2.41]; p = 0.035) compared to a normal β2 microglobulin. On subgroup analysis, however, elevated β2 microglobulin remained significantly associated with worse OS/CSS only in patients with normal renal function and non-metastatic disease (Table). Conclusions: A preoperatively elevated β2 microglobulin level is independently associated with worse OS and CSS in patients with RCC undergoing nephrectomy. The utility of β2 microglobulin as a prognostic indicator is most relevant for patients with normal renal function and non-metastatic disease. Multivariable Cox hazards model for the effect of preoperative β2 microglobulin on cancer-specific and overall survival in patients with renal cell carcinoma according to renal function and metastatic disease status. Covariants n(%) Cancer-specific SurvivalHazard Ratio (95% CI) p-value Overall SurvivalHazard Ratio (95% CI) p-value β2 microglobulin ≥ 2.34 mg/L metastatic disease 102 (63) 0.95 (0.51-1.76) 0.872 0.93 (0.56-1.55) 0.779 non-metastatic disease 76 (28.5) 4.55 (1.24-16.77) 0.023 2.99 (1.37-6.54) 0.006 eGFR ≤ 60* 99 (23.1) 1.31 (0.69-2.49) 0.410 1.51 (0.95-2.41) 0.083 eGFR > 60* 79 (18.4) 2.90 (1.54-5.44) < 0.001 2.00 (1.19-3.36) 0.009 β2 microglobulin < 2.34 mg/L eGFR ≤ 60* 50 (11.7) 1.24 (0.55-2.78) 0.600 1.39 (0.74-2.60) 0.309 eGFR > 60* 201 (46.9) Ref Ref *Calculated using Chronic Kidney Disease Epidemiology Collaboration 2021 equation. Variables in model include age, sex, race, Body Mass Index (BMI), Charlson Comorbidity Index (CCI) pT stage, Fuhrman grade, presence of IVC thrombus, receipt of systemic therapy, and IMDC risk score (metastatic patients only).
Sociodemographic predictors of the late-stage diagnosis in patients with prostate cancer: A retrospective cohort study.
132 Background: Distant metastasis at the time of prostate cancer (PCa) diagnosis is associated with increased morbidity and mortality. This study aimed to assess the impact of sociodemographic characteristics on distant metastasis at the time of PCa diagnosis. Methods: The Surveillance Epidemiology and End Results (SEER) database (2000-2021), including PCa patients from 17 registries, was queried. Patients with late-stage diagnosis (LSD) were defined as those who were initially diagnosed with stage IV disease, indicating distant metastasis. Sociodemographic predictors included race, ethnicity, age, marital status, residential status, and median household income. Multicollinearity was assessed using variance inflation factors (VIF). Univariable logistic regression was performed to identify significant predictors of LSD, which were further analyzed in multivariable logistic regression using a maximum likelihood estimation approach. Odds ratios with 95% confidence intervals (CI) were computed with a p-value of <0.05 indicating a statistically significant association. Results: Of the 1,089,736 PCa patients diagnosed, 64,983 (6%) had an LSD. The majority were white (80%), non-Hispanic/Latino (HL) (91%), aged ≥65 years (60%), married (75%), residents in metropolitan areas (88%), and had an annual house income of ≥$70,000 (70%). Multivariable logistic regression identified Black (OR: 1.24; 95%CI: 1.22-1.27), Asian or Pacific Islander (1.35; 1.30-1.40), and American Indian/Alaska Native (1.70; 1.53-1.89) to have higher odds of LSD compared to White patients (Table). In addition, HL ethnicity compared to non-HL (OR: 1.45; 95% CI: 1.42-1.49), age ≥65 compared to <65 (1.68; 1.65-1.71), unmarried status compared to married (1.88; 1.85-1.91), residency in non-metropolitan areas compared to metropolitan (1.10; 1.07-1.12), and household income <$70,000 compared to ≥$70,000 (1.03; 1.01-1.05) had a significant association with LSD. Conclusions: Older, non-White (Black, Asian/Pacific Islander, American Indian/Alaska Native), Hispanic/Latino, unmarried men, residents of non-metropolitan areas, or those with lower annual household incomes have higher odds of late-stage diagnosis. Interventions targeting early detection in these at-risk groups may improve prostate cancer outcomes in the US. Variable Odds Ratio (95% CI) p-value Race (Black vs White) 1.24 (1.22-1.27) <0.01 Race (Asian or Pacific Islander vs White) 1.35 (1.31-1.40) <0.01 Race (American Indian/Alaska Native vs White) 1.70 (1.53-1.89) <0.01 Ethnicity (Hispanic/Latino vs non-/Hispanic/Latino) 1.45 (1.42-1.49) <0.01 Age (≥65 vs <65) 1.68 (1.65-1.71) <0.01 Marital status (unmarried vs married) 1.88 (1.85-1.91) <0.01 Residence status (non-metropolitan vs metropolitan) 1.10 (1.07-1.12) <0.01 Household income (<$70,000 vs ≥$70,000) 1.03 (1.01-1.05) <0.01
Approach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America.
263 Background: Randomized clinical trials have demonstrated the efficacy of both doublet (androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPi)) and triplet (ADT + ARPi + docetaxel) regimens in the treatment of mHSPC. However, the optimal clinical setting for each approach remains unclear. We surveyed genitourinary oncologists to identify their practice patterns with respect to systemic therapy for mHSPC. Methods: A 13-question survey was distributed to clinicians associated with the Canadian Clinical Trials Group (CCTG), SWOG, and Alliance for Clinical Trials in Oncology between March 2024 and June 2024. We collected data on clinician specialty, practice setting, location, years of clinical experience, and approach to management for patients with mHSPC. Results: 542 responses were solicited, and 104 (19%) surveys were completed. 24 respondents were from Canada (CCTG) and 80 were from the United States (47 SWOG, 33 Alliance). 88% (92/104) respondents indicated that less than 50% of their mHSPC patients are started on triplet therapy (Table). The most important factors when considering the use of doublet vs. triple therapy were volume of disease (88/104, 85%) and patient comorbidities (82/104, 79%). Physicians favored triplet therapy in high volume, de novo (95/104, 91%) or recurrent (70/104, 67%) disease, but not in low volume, de novo (2/104, 2%) or recurrent (2/104, 2%) disease. The greatest barriers to triplet therapy were toxicity concerns (75/104, 72%) and patient factors (66/104, 63%). In the scenario where prostate specific antigen (PSA) remained at 4 ng/ml after 6 months of doublet therapy, 77% (80/104) would not make any changes, while 23% (24/104) could consider additional intensification strategies, including clinical trial enrollment. In the scenario where PSA was undetectable after two years on doublet therapy, 63% (65/104) would continue therapy without de-escalation, while 37% (38/104) would consider deintensification, and 1 declined to answer. Responses were concordant between American and Canadian participants. Conclusions: North American genitourinary oncologists consider disease volume, patient comorbidities, and toxicity when opting for doublet vs. triplet therapy, and feel there is a role to explore PSA-based de/intensification strategies in future clinical trials. Alliance (n = 33) SWOG (n = 47) CCTG (n = 24) Total (n = 104, %) Specialty Medical Oncology 32 39 24 95 (91%) Radiation Oncology 0 4 0 4 (4%) Surgical Oncology 0 3 0 3 (3%) Other 1 1 0 2 (2%) Practice setting Academic 31 41 24 96 (92%) Private 0 1 0 1 (1%) Other 2 5 0 7 (7%) Years from fellowship <5 years 11 8 6 25 (24%) 5-10 years 6 10 5 21 (20%) 10-20 years 8 15 9 32 (31%) >20 years 8 13 4 25 (24%) Other / Skipped 0 1 0 1 (1%) Percent of patients offered triplet therapy <10% 9 14 8 31 (30%) 11-30% 12 20 13 45 (43%) 31-50% 7 9 0 16 (15%) 51-75% 3 3 2 8 (8%) >76% 2 1 1 4 (4%)
A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy.
264 Background: In mCRPC, standard risk models use baseline clinical and blood-based biomarkers, excluding imaging. This study developed a new predictive model incorporating baseline and early on-treatment clinical, blood, and imaging biomarkers to inform overall survival (OS). The training set was derived from COU-AA-302 and validated using Alliance 031201 (A031201). Eligibility required patients to have at least two CT and bone scans within 6 months of randomization (COU-AA-302: n = 785; A031201: n = 582). Methods: Conventional biomarker data included PSA, albumin, alkaline phosphatase, hemoglobin, and ECOG status. Imaging data included > 1000 radiomic features and the automated Bone Scan Index (aBSI). Six-month biomarker trajectories were summarized using the intercept and slope from a random effects model, yielding over 2000 risk biomarkers. Due to the high dimensionality, an elastic net proportional hazards model was applied. Predictive concordance probability, which evaluates the ability to distinguish between long-term and short-term survivors, and R-square, a calibration measure that indicates how accurately the model predicts actual survival time were determined. Results: 46 biomarkers were selected from over 2000, including 9 blood-based, 4 from aBSI, 1 tumor volume measure, and the remaining from radiomic features. In contrast, the non-imaging risk model contained 10 risk factors. Risk scores from these models were categorized into low, moderate, and high-risk groups. The median survival per group revealed significant separation, with a difference of over 30 months between low and high-risk groups. This separation was observed regardless of whether imaging was included in the model. Conclusions: This is the first model for mCRPC to integrate pre-treatment and early on-treatment serum, imaging, and clinical data from two large phase 3 trials, with external validation. While both imaging and non-imaging models showed good predictive accuracy, imaging did not significantly improve the discrimination of long-term from short-term survivors or enhance the precision of the model-based survival predictions. Clinical + Serum biomarkers with imaging Clinical + Serum biomarkers without imaging Total # of risk factors 46 10 # of clinical/serum factors 9 10 # of radiomics factors 32 0 # of aBSI factors 4 0 # of tumor volume factors 1 0 Median Survival (mos) Low risk group 55 54 Moderate risk group 38 39 High risk group 20 21 Predictive Concordance Probability 0.74 0.73 R-square Measure of Calibration 0.37 0.39
Cancer-control outcomes of metastatic castration resistant prostate cancer patients with <i>BRCA</i> -gene or tumor suppressor mutations undergoing 177-lutetium PSMA radioligand therapy.
71 Background: Several tumor gene mutations are known for metastatic castration-resistant prostate cancer (mCRPC) are known. The individual response to 177-Lutetium Prostate-specific membrane antigen (Lu-PSMA) therapy is under current investigation regarding the genomic profile of mCRPC patients. Methods: We relied on the FRAMCAP database and compared progression-free (PFS) and overall survival (OS) rates of mCRPC patients with Breast Cancer related antigen ( BRCA ) or tumor suppressor gene mutations ( TP53, PTEN, RB1 [TSG]). Especially, subgroup analyses were performed for Lu-PSMA-treated mCRPC patients. Results: Of 194 mCRPC patients, 22% were BRCA1/2 vs. 14% TSG vs. 63% without one of these mutations. Patients with no mutation harbored significantly lower Gleason score 8-10, relative to BRCA and TSG patients. In PFS analyses of first line mCRPC, no difference between all three groups was observed, while median OS differed significantly with 46.3 vs. 48.7 vs. 95.4 months for BRCA vs. TSG vs. no mutated patients (p<0.05). In univariable Cox regression models, BRCA mutated patients were at higher risk for death (hazard ratio [HR]: 2.57, p<0.01), while TSG patients were not (p=0.4). Of 87 Lu-PSMA treated mCRPC patients, significant differences in PFS and OS were made (both p≤0.02). In univariable and multivariable Cox regression models, BRCA mutated Lu-PSMA patients were at higher risk for death, while TSG patients had similar outcomes as no mutated patients. Conclusions: In real-world setting, substantially lower OS in mCRPC is observed for BRCA and TSG mutated patients, while no difference in first line PFS could be computed. In Lu-PSMA-treated patients, worst outcomes were observed for BRCA patients. Age at mCRPC, years 149 68 (61, 75) 66 (61, 71) 69 (65, 80) 69 (63, 76) 0.3 PSA at CRPC, ng/ml 105 12 (3, 50) 12 (1, 72) 5 (3, 36) 13 (4, 46) 0.8 Treatment lines mCRPC 194 3.00 (1.00, 4.00) 3.00 (1.00, 4.50) 3.00 (1.00, 4.00) 3.00 (1.00, 4.00) 0.6 ECOG status at mCRPC 79 0.017 0 47 (59%) 7 (44%) 12 (92%) 28 (56%) 1 32 (41%) 9 (56%) 1 (7.7%) 22 (44%) ≥2 0 (0%) 0 (0%) 0 (0%) 0 (0%) Cardiovascular disease 168 52 (31%) 9 (23%) 6 (21%) 37 (37%) 0.15 Gleason Score 179 0.032 8-10 130 (73%) 34 (83%) 22 (81%) 74 (67%) De Novo mHSPC 186 123 (66%) 32 (76%) 18 (64%) 73 (63%) 0.3 High volume mHSPC 126 73 (58%) 24 (71%) 12 (63%) 37 (51%) 0.13 Metastatic sites at mCRPC 92 0.2 M1a 6 (6.5%) 1 (4.5%) 2 (10%) 3 (6.0%) M1b 75 (82%) 15 (68%) 17 (85%) 43 (86%) M1c 11 (12%) 6 (27%) 1 (5.0%) 4 (8.0%) PARPi Treatment 194 25 (13%) 15 (35%) 1 (3.6%) 9 (7.3%) <0.01 1 Median (IQR); n (%). 2 Kruskal-Wallis rank sum test; Fisher’s exact test; Pearson’s Chi-square test.
Feasibility and efficacy of cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer in older patients: A retrospective French GETUG study.
735 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) and radical cystectomy is the gold standard in localized muscle-invasive bladder cancer (MIBC), for fit patients. However, NAC is less prescribed in older patients, mainly due to safety concerns. This study aimed to evaluate the feasibility and efficacy of NAC for patients aged ≥ 75. Methods: We retrospectively included older patients, from 14 French GETUG centers. All patients had received at least one cycle of cisplatin-based NAC for localized MIBC, between 2010 and 2022. Primary outcome was NAC feasibility evaluated as the rate of patients that underwent optimal treatment, defined as at least 4 cycles of chemotherapy followed with local treatment (surgery or chemoradiotherapy). Secondary outcomes were NAC safety and efficacy. Results: 156 pts were included. Median age was 77 (from 75 to 96), with 20% aged ≥ 80. Patients were in good general condition: 54% were PS 0, with a median serum albumin level of 39 g/L, and 86% had a creatinine clearance ≥ 60 ml/min. 108 (69%) had a cT2N0 MIBC. 75 (48%) received dose dense MVAC (ddMVAC), 80 (51%) received gemcitabine-cisplatin (GC) and one patient received MVAC. 96 (62%) received an optimal treatment. 50 patients (32%) prematurely stopped NAC, due to death (3 pts, 2 from unknown causes), progressive disease (4), infection (3), toxicity (34 patients) mainly renal and hematological ones. Among them, 38 (76%) underwent local treatment. Among the 112 patients that underwent cystectomy, pathological complete response (pCR) was significantly more frequent when they received ≥ 4 cycles (36/78 = 46% versus 5/34 = 15%, p = 0.002). Median follow up from diagnosis was 28 months, with 97 patients (62%) that were still alive at the end of follow-up. Median disease-free survival was 3 years and 3 months. 2-years overall survival (OS) was 72%; 5-years OS was 56%. Conclusions: These data suggest that NAC for MIBC is feasible in selected older patients, even if toxicity was the main reason for cisplatin-based regimen discontinuation. Older patients who received optimal treatment were more often in pCR. OS in the this cohort of older patients was very similar to the results published in younger patients.
Leveraging tumor organoids to model drug response in clear cell renal cell carcinoma.
579 Background: Clear cell renal cell carcinoma (ccRCC) is characterized by a highly immunosuppressive tumor microenvironment that plays a crucial role in promoting tumor progression and conferring resistance to conventional treatments, such as chemotherapy and radiotherapy. Systemic therapies, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), have become central to the management of ccRCC. However, patient responses to these treatments vary significantly. Given the pivotal role of ICIs in ccRCC therapy, recreating the tumor-immune microenvironment in vitro is essential to address the current lack of reliable biomarkers. Patient-derived tumor organoids (PDTOs) offer a highly accurate platform for evaluating drug efficacy tailored to individual patients, significantly enhancing therapeutic decision-making. These models closely replicate the three-dimensional architecture, genetic profile, and behavior of the original tumor tissue. Moreover, PDTOs can be co-cultured with various cell types, such as cancer-associated fibroblasts (CAFs) and immune cells, to simulate the tumor-immune microenvironment. The aim of our study is to set an in vitro drug screening by providing more physiologically relevant PDTOs which could enable researchers to study how therapies, especially TKIs and ICIs, interact with both tumor and immune cells. Methods: This is a translational on-going study including patients with diagnosis ccRCC. We successfully established five patient-derived ccRCC PDTO lines from individuals who underwent partial or radical laparoscopic robotic assisted nephrectomy. All the models faithfully recapitulated the original tumors at both the histological and genetic levels, harboring somatic mutations in key genes such as VHL (50%), PBRM1 (30%), SETD2, and BAP1. The PDTOs were treated with standard-of-care compounds, including Cabozantinib, Lenvatinib, and Axitinib, and the resulting dose-response curves observed. Results: When co-cultured with autologous cancer-associated fibroblasts (CAFs) and immune cells, and treated with the same compounds, the PDTOs exhibited different response patterns compared to PDTOs alone, indicating that the tumor microenvironment significantly modulates drug response. We tested Ipilimumab, Nivolumab, and Pembrolizumab in our co-culture system, both as monotherapies and in combination. The resulting dose-response curves revealed heterogeneous levels of drug sensitivity and resistance. Conclusions: In conclusion, by faithfully replicating the tumor microenvironment and facilitating comprehensive drug screening, this approach aims to identify optimal treatment regimens and uncover mechanisms of resistance. Ultimately, it seeks to create a personalized, predictive model that can enhance clinical decision-making in the management of ccRCC.